Nicholette Erickson, MD
Hematology & Oncology · Lynchburg, VANPI 1063488518
Payments from drug & device makers
Across 164 payments — averaging $405.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$48K
- Puma Biotechnology, Inc.$15K
- Astrazeneca UK Limited$914
- AstraZeneca$698
- Johnson & Johnson$346
- E.r. Squibb & Sons, L.L.C.$183
- plus $2K from 26 others
Across 2 payments — averaging $540.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
What the payments were for
- Food & beverage$2,91290%
- Education$32810%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 20 | $47,670 |
| Puma Biotechnology, Inc. | 3 | $14,703 |
| Astrazeneca UK Limited | 4 | $914 |
| AstraZeneca | 28 | $698 |
| Johnson & Johnson | 14 | $346 |
| E.r. Squibb & Sons, L.L.C. | 8 | $183 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $175 |
| AbbVie | 6 | $172 |
| Pfizer | 9 | $168 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $166 |
| Novartis | 7 | $154 |
| Astellas Pharma US Inc | 3 | $137 |
| Seagen Inc. | 3 | $129 |
| Amgen | 5 | $98 |
| Daiichi Sankyo Inc. | 4 | $98 |
| Merck | 5 | $94 |
| Bristol Myers Squibb | 5 | $75 |
| GSK | 3 | $68 |
| Lilly USA, LLC | 3 | $59 |
| Stemline Therapeutics Inc. | 3 | $59 |
| Array Biopharma Inc | 3 | $55 |
| Karyopharm Therapeutics Inc. | 2 | $50 |
| Beigene USA, Inc. | 2 | $40 |
| Exelixis Inc. | 1 | $32 |
| Genentech USA, Inc. | 2 | $31 |
| Bayer | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Sobi, Inc | 1 | $23 |
| EMD Serono, Inc. | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Gilead | 1 | $12 |
| Incyte Corporation | 1 | $12 |
How this compares
$66,503 in reported general payments places this provider in the 70th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 34 | $799,897 |
| ImbruvicaIbrutinib | 36 | $640,448 |
| Lenalidomide | 33 | $561,167 |
| IbrancePalbociclib | 20 | $326,035 |
| PomalystPomalidomide | 16 | $321,485 |
| XtandiEnzalutamide | 22 | $316,907 |
| TazverikTazemetostat Hydrobromide | 13 | $236,263 |
| LonsurfTrifluridine/Tipiracil Hcl | 17 | $189,984 |
| KisqaliRibociclib Succinate | 11 | $179,404 |
| NinlaroIxazomib Citrate | 11 | $143,450 |
| OxycontinOxycodone Hcl | 18 | $32,301 |
| XareltoRivaroxaban | 17 | $18,548 |
| CreonLipase/Protease/Amylase | 12 | $9,681 |
| Anastrozole | 304 | $6,864 |
| Xtampza ErOxycodone Myristate | 11 | $5,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $75 | $799,89734 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $175 | $640,44836 claims |
| PfizerIbrance | $168 | $326,03520 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $183 | $321,48516 claims |
| Astellas Pharma US IncXtandi | $137 | $316,90722 claims |
| NovartisKisqali | $154 | $179,40411 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $166 | $143,45011 claims |
| Johnson & JohnsonXarelto | $346 | $18,54817 claims |
| AbbVieCreon | $172 | $9,68112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Lynchburg
- Craig PortellCharlottesville$12.9M
- Amanda Gillespie-TwardyRoanoke$12.2M
- Sekwon JangFairfax$11.8M
- Mark FlemingHampton$10M
- Mark KochenderferRoanoke$8.6M
- Mitul GandhiManassas$6.9M
- Michael DansoNorfolk$6.9M
- Jerome GoldschmidtChristiansburg$6.5M
- William IrvinMidlothian$4.3M
- Lakshminarayanan NandagopalFredericksburg$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.